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ABSTRACT 
Infectious diseases derive from organisms such as viruses, bacteria, fungi and 
parasites that can be passed from person to person, transmitted via bites from insects or 
animals, or acquired through ingestion of contaminated food or water or environmental 
exposure. Infectious diseases cause roughly 20% of annual deaths worldwide, including 
many children under the age of five. In developing countries, these diseases remain a 
major public health problem. They can also cause societal and economic burdens through 
life-long disability. We need a better understanding of these diseases with a view towards 
the goals of prevention and cure.  
The advent of whole-genome transcriptional profiling technology and powerful 
computational resources has made it possible to study infectious diseases on a genome-
wide scale. Such studies can lead to improvements in diagnostic tools as well as 
preventive measures such as vaccines. The work of this thesis focuses on a number of 
projects with the common thread of developing and applying of computational methods 
to extract biological information from high-throughput transcriptional data related to 
infectious diseases. These include (1) the identification of gene signatures related to B-
	  	   viii 
cell proliferation that predict an influenza vaccine-induced antibody response; (2) study 
of the physiological state of the Plasmodium falciparum malaria parasite when 
sequestered in human tissue; (3) identifying the similarity and differences of the response 
to five anti-viral vaccines.  To achieve the scientific goals of these projects I developed 
two new computational methods that can be utilized more broadly for the downstream 
interpretation of results from enrichment analyses of whole transcriptome profiles.  There 
are a combined visualization and annotation approach called the Constellation Map and 
the Leading Edge Metagene Detector that systematically consolidates functionally related 
genes from multiple sets representing highly enriched biological pathways and processes 
in the comparison of expression data of two biological phenotypes. The application of 
those computational approaches and tools in this dissertation enabled a better 
understanding of the biological mechanisms related to human vaccine response. The 
software packages developed are freely available for use by biological investigators 
across many fields. 
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CHAPTER 1 INTRODUCTION  
Infectious diseases are derived from microorganisms such as viruses, bacteria, 
fungi and parasites. They account for around 20% of annual deaths worldwide, including 
many children under the age of five [1]. In developing countries, these diseases remain a 
major public health problem. They can also cause societal and economic burdens through 
life-long disability. Thus, we need a better understanding of these diseases with a view 
towards the goals of prevention and cure.   
 In the projects described in this dissertation, I developed and applied 
computational methods and software tools to understand infectious diseases. In Chapter 
2, I will describe a knowledge-based predictor of vaccine efficacy. Vaccination is one of 
the most effective methods of preventing human disease. However many vaccines are not 
universally protective, and even widely used vaccines, such as those targeting influenza, 
fail to achieve protective immunity in a significant proportion of vaccinated subjects[4]. 
Identifying the biological features of the early vaccine response that predict the 
subsequent development of vaccine immunity is therefore a central goal in human 
immunology. Recently, whole-genome transcriptional profiling has been used to 
understand infectious disease. For example gene expression profiles of peripheral blood 
mononuclear cells (PBMC) in vaccinated individuals have been used to predict the 
development of protective immunity[2], [3]. However, the magnitude of change in 
individual genes’ expression between vaccine responders and nonresponders is likely to 
be small and distributed across networks of genes, making the selection of predictive and 
biologically relevant single genes difficult. Through the application of gene set 
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enrichment analysis (GSEA) and machine learning algorithms, we showed that signatures 
consistent with proliferating B cells predict antibody response to influenza vaccination. 
While doing this project, I developed Constellation Map, a concise and informative 
visualization framework for gene set enrichment analysis on a single sample level and 
that also serves as a general approach for feature selection. At the end of Chapter 2, I will 
describe the details of this novel method as well as introduce a JavaScript-powered web 
app based on this method co-developed by myself and Felix Wu. In Chapter 3, I will 
introduce a project applying two new techniques for measuring gene expression of 
malaria parasites sequestered in patient tissues. Using a set of nCounter® malaria gene 
probes, we quantified malaria gene expression in vivo, first in a validation set of 
peripheral blood samples and then in a set of malaria-infected human tissue samples 
collected at autopsy. Furthermore, to study the gene expression profiles of malaria 
parasites on a whole-genome scale, I applied a whole-genome imputation algorithm [5] to 
generate genome-wide transcriptional profiles for each sample, providing a first look at 
the gene expression profiles of in vivo sequestered malaria parasites. Chapter 4, I will 
introduce an analysis approach for identifying modules of genes which we term “leading 
edge metagenes” (LEM) that are both common to multiple, significantly enriched leading 
edge subset of gene sets, and coordinately enriched in a phenotypic comparison of 
interest. The leading edge of a gene set consists of those genes that “drive” the 
enrichment score in a GSEA analysis[6]. I applied this approach to analyze the 
transcriptional response induced by five different vaccines measured in PBMCs. This 
analysis demonstrates that different vaccines initially elicit distinct, biologically coherent 
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patterns of gene expression three days after vaccination and that these transcriptional 
patterns of response become more similar with increasing time after vaccination. This 
method has also been applied to the analysis of the transcriptional response to sepsis in 
human samples and mouse models. The results suggest that there is highly significant 
conservation and species-specific differences of gene expression between the species 
when measured at the gene set level. 
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CHAPTER 2 KNOWLEDGE-BASED PREDICTOR OF VACCINE 
EFFICACY 
The work described in sections 2.1- 2.4 appeared in the European Journal of 
Immunology [7] and the text is excerpted from that publication. Part of the text in section 
2.5 is excerpted from a manuscript I co-authored with Felix Wu, entitled “Constellation 
Map: A software package for downstream visualization and interpretation of enrichment 
results”. That manuscript will be submitted to the journal Bioinformatics at the second 
quarter of 2015. 	  
2.1 Background 
Vaccination is one of the most effective methods of preventing human disease. 
However many vaccines are not universally protective and even widely used vaccines, 
such as those targeting influenza, fail to achieve protective immunity in a significant 
proportion of vaccinated subjects[4]. Identifying the biological features of the early 
vaccine response that predict the subsequent development of vaccine immunity is 
therefore a central goal in human immunology. 
New investigative tools such as gene expression profiling have begun to be 
applied to the problem of predicting vaccine response[8]. Most of these approaches have 
assayed vaccine-induced changes in gene expression in the PBMC compartment, a 
bellwether of changes at distant vaccine sites. Two studies have shown that changes in 
the expression of small numbers of genes in PBMC gene expression profiles a few days 
after vaccination predict the subsequent magnitude of the immune response measured 
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several weeks later[9], [10]. These studies suggest that gene expression profiles from 
PBMC samples in vaccinated subjects can provide predictors of the vaccine response. 
However there are two significant challenges to developing gene expression based 
predictors of clinical outcome following vaccination. First, the extent of biological 
change in PBMC caused by direct interaction with the vaccine and PBMC would be 
expected to be small. While live attenuated vaccines like those developed against yellow 
fever (YF-17D) are known to replicate systemically and induce readily detectable 
interferon responses[2], [10], [11], non-replicating subunit vaccines such as those against 
influenza would be expected to have a much smaller effect on the transcriptional profile 
of PBMC. Thus the selection of individual genes that are strongly associated with 
response to vaccination can be challenging. 
The second challenge is that the biological meaning of gene expression-based 
predictors is often hard to determine[9], [10]. One reason for this is that the analytic 
approaches to identify predictive genes are often different from those used to discover 
biological mechanisms evident in gene expression data. Predictive genes are selected on 
statistical rather than biological grounds[12] which tends to divorce the identity of the 
predictive genes from an understanding of their role in vaccine biology[13]. 
To address these limitations, rather than building a predictive model based on 
single differentially expressed genes in PBMC, we used sets of coordinately regulated, 
biologically informative gene sets as predictive features in individual samples[14], [15]. 
As a source of gene sets, we use a compendium of signatures extracted from the 
published literature and from expert curation[16]. These signatures represent phenotypes 
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of defined cell states and biological perturbations, providing specific biological contexts 
with which to interpret the predictive models.  Moreover, this approach allows changes in 
networks of genes to be used as predictive features even though the magnitude of change 
in any individual constituent gene is small[17].   
I show that this approach enabled the development of gene expression predictors 
from genes directly related to biological processes that a conventional single-gene level 
predictor does not identify. I applied this approach to pinpoint the biological hallmarks of 
response of two different vaccines, and show that signatures consistent with proliferating 
B cells predict antibody response to influenza vaccination. 	  	  
2.2 Results 
2.2.1 YF-17D induces signatures of interferon and inflammatory response 
We began by analyzing PBMC microarray data from individuals vaccinated with 
the yellow fever virus vaccine (YF-17D). YF-17D is a highly potent vaccine that induces 
a robust interferon gene response in post-vaccination PBMC samples[2], [10], [11].  In 
this small data set, our goal was not to identify predictors of response, but rather to test 
whether a gene set-based analytic approach could recover known biological features of 
the effect of YF-17D vaccination such as the interferon response. To identify sets of 
genes – rather than individual genes – that were elicited by YF-17D, we used a variant of 
GSEA[18]. GSEA is an analytic approach that tests for enrichment of an a priori set of 
genes in a rank-ordered list of genes. Such a rank-ordered list of genes is usually created 
by comparing the average expression values of genes in a group of microarray samples to  
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Figure 2.1 YF-17 vaccination induces upregulation of gene sets related to interferon response.   
(A) Heatmap of the top 20 gene sets enriched in day seven samples compared with day 0 samples, with 
color indicating ssGSEA enrichment scores for each gene set in each sample. Gene sets are ranked by the 
normalized mutual information score. DAVID annotation of gene sets are indicated in the bar on the left; 
orange indicates a signature enriched for the GO term “Response to Virus”; purple “Response to Stimulus”. 
(B) Constellation Map visualization of the top scoring 20 gene sets. Purple arc indicates gene-sets indicated 
on the right in (A). Green lines indicate two gene sets sharing genes in common, and the thickness is 
proportional to Jaccard index. Data shown are the top 20 most enriched gene sets in day seven samples out 
of ~900 significantly (FDR < 0.25) enriched gene sets. 
 
those in a control group. Enrichment is measured by the degree of over representation of 
the set of genes of interest at the top (or bottom) of the rank ordered list. Because we 
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wanted to test for enrichment of gene sets in individual samples from vaccinated patients 
(rather than in a group of samples from vaccinated subjects), we used a single sample 
version of GSEA (ssGSEA)[19]. In this approach, gene sets are tested for enrichment in 
the list of genes in a single sample ranked by absolute expression rather than by 
comparison with another sample.  
We analyzed Affymetrix expression profiles of 15 individuals obtained pre-
vaccination (Day 0) and seven days following vaccination (Day 7). We used ssGSEA to 
test each sample for enrichment of signatures from the Molecular Signatures Database 
(MSigDB) [20] using ~3,000 gene sets that have been collected by curation of published 
microarray studies, or are present in pathway databases such as Reactome (described in 
Section 2.2 Methods)[16].  
We found that ~900 gene sets were significantly (FDR < 0.25) enriched in the 
Day 7 post-vaccine samples (Figure 2.1A), suggesting marked differences in gene 
expression profile following vaccination with YF-17D. To identify whether the gene sets 
represented similar biological processes we tested the gene sets for similarity to each 
other using two approaches. First, we used the DAVID annotation tool[21] to categorize 
the genes in each gene set and found that the majority of gene sets were strongly 
associated with the interferon or inflammatory response (Figure 2.1A).  
Next, we developed a new visualization and analysis method — Constellation 
Map — to identify similarities between gene sets whose enrichment correlated with a 
phenotype of interest (Figure 2.1B). In this analysis, we project each significantly 
enriched gene set onto a radial plot.  Gene sets that are closer to the center are more 
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enriched in samples of the phenotype of interest (Day 7, post-vaccination). Gene sets that 
are similar to each other in terms of enrichment patterns will be clustered closely 
together. To further discern similarities between the gene sets, we connected gene sets 
with edges whose thickness is proportional to the fraction of genes that they have in 
common. Groups of gene sets that both show a similar pattern of enrichment in the 
phenotype of interest and also share genes in common can be easily identified and are 
indicated by the arc on the perimeter of the radial plot. Using this method, we found that 
the majority of the gene sets enriched in Day 7 samples formed a single highly-connected 
cluster, suggesting that the top-scoring gene-sets shared a set of genes related to a 
predominant biological process. (Figure 2.1B). Analysis of the genes common to this 
cluster of gene sets again showed a striking over representation of interferon response 
genes consistent with our previous work[10]. Thus the gene sets that are correlated with 
Day 7 post YF-17D status are associated with a single predominant biological process – 
interferon response. These findings agree with the up-regulation of individual interferon 
response genes in response to YF-17D vaccination previously observed[10], and suggest 
that a gene set-based analytic approach can capture known biological features of the 
effect of vaccination with a live viral vaccine on PBMC.  
2.2.2 Vaccine response to trivalent inactivated influenza vaccine (TIV) is correlated with 
cell proliferation and immunoglobulin gene signatures 
Having validated the analytic approach in samples from subjects vaccinated with 
YF-17D, we next applied gene set based analysis to a more challenging problem: 
identifying features that predict the antibody response to the inactivated influenza 
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vaccine. We analyzed PBMC profiles from individuals vaccinated with the trivalent 
inactivated influenza vaccine (TIV) that were collected pre-vaccination (Day 0) and 7 
days post vaccination [16]. Hemagglutination inhibition (HAI) titers for each subject 
were available pre-vaccination and 28 days post vaccination and were used as the 
outcome measure of vaccine response. We calculated the magnitude of antibody 
responses to the vaccine (HAI response) as the maximum difference between the HAI 
titer at day 28 and the baseline titer (day 0) for any of the three influenza strains 
contained in the vaccine. We classified the vaccinated subjects as low or high HAI 
responders based on whether or not a fourfold increase in titer occurred after vaccination. 
This criterion was based on our prior study[22], and on the US Food and Drug 
Administration Guidance for Industry document for this field[23].  Using this criterion, 
17 vaccinees had a high HAI response and 7 had a low HAI response. 
To identify gene sets that correlated with a high HAI response, we compared the 
PBMC gene expression profile of each individual at Day 7 with the corresponding profile 
from Day 0, to create a list of genes ranked by their fold changes after vaccination for 
that subject. We then tested each subject’s vaccine response for enrichment of gene sets 
from the same database collection as used before using ssGSEA and identified the gene 
sets most differentially enriched in the high responders compared with the low 
responders. We found 13 gene sets significantly associated with a high HAI response to 
vaccine (FDR < 0.25) (Figure 2.2A). The number of gene sets and degree of enrichment 
of gene sets correlated with TIV antibody response was lower than what we observed in 
the comparison of pre and post YF-17D vaccination. This suggests that the biological  
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Figure 2.2  Antibody response to TIV correlates with enrichment of proliferation and 
immunoglobulin gene sets.   
(A)  Heatmap of the top 13 gene sets (FDR < 0.25) enriched in high responders (yellow) compared to low 
responders (green). Gene sets are ranked by the mutual information score. (B) Constellation Map of the top 
13 gene sets. Two connected clusters of gene sets are detected in the constellation map, indicated by orange 
and lilac arcs. (C and D) Protein-Protein interaction network of two connected clusters in (B). Significant 
physical connectivity is shown for genes within the antibody cluster (C, orange) and proliferation cluster (D, 
lilac).  
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"signal" associated with influenza vaccine response is less pronounced than the effect of 
vaccination with YF-17D. 
The gene sets that were enriched in responders were from a wide array of studies 
and sources and the genes in most gene sets were non-redundant, suggesting that the gene 
sets represented diverse biologies.  However, using Constellation Map we found two 
distinct but connected clusters of gene sets (Figure 2.2B). We used DAVID annotation as 
a tool to provide secondary annotation for the two clusters of genes and found that one 
cluster (indicated by the orange arc) was strongly enriched for immunoglobulin and 
complement genes. The second cluster (indicated by the purple arc) was strongly 
enriched for genes associated with proliferation. 
We reasoned that if these clusters of highly connected gene sets enriched in 
samples from vaccine responders represented bona fide biological processes, then the 
genes shared by each of these clusters should be over-represented for physically 
interacting genes. To test this, we projected the genes found in the gene set clusters into 
InWeb[24] a curated protein-protein interaction network (PPI; Figures 2.2C and 2.2D). 
We found that there was a high degree of physical connectivity between the component 
genes of the antibody gene cluster (P = 10-3), and between the genes in the proliferation 
cluster (P = 10-2) (Figures 2.2C and 2.2D). This suggests that the clusters of enriched 
gene sets found in responders represented coordinated up-regulation of genes in 
functional networks.  
We confirmed these findings using a second, independent source of gene sets, 
described by Chaussabel et al.[25] and again found that the best-scoring module of genes 
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was related to B cell biology, although individual modules from that collection did not 
score as highly as those contained in the MSigDB. (Data not shown) 
 
Figure 2.3 Model fit of response to TIV using proliferation and immunoglobulin gene.  (A and B)  
Logistical Regression Model of probability of vaccine response for proliferation (A, 
CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP) and immunoglobulin (B, 
REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT) gene set enrichment scores. (C) Combined 
model using Bayes rule. 
 
We compared the performance of gene sets with their constituent genes in profiles 
from high versus low HAI responders to influenza vaccination. We found that the top-
scoring gene sets in TIV responders were more strongly correlated with the high antibody 
response phenotype than any constituent gene in either gene set.(Data not shown) 
Moreover, although both complement and antibody genes were present in gene sets 
enriching in responders, the antibody genes were among those most up-regulated. Thus a 
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gene set-based analytic approach identifies signatures of proliferation and 
immunoglobulin genes that are strongly correlated with high antibody response. 
2.2.3 Immunoglobulin and proliferation gene sets accurately predict vaccine response to 
TIV. 
We next sought to determine if enrichment of the immunoglobulin and/or 
proliferation gene sets could be used as a predictor of vaccine response, using high or low 
HAI titers as an outcome. To do this, we selected the most differentially enriched gene 
set from each of the two clusters, and fitted them into logistic regression models. Both 
models closely fit the data and yielded an AUC of ~0.9 (Figure 2.3A and 2.3B), 
suggesting that each independent gene set could provide a strongly predictive model of 
vaccine response. To integrate both biological processes into a single model, we applied 
Bayes’ rule, and found that the integrated model achieved an AUC of 0.94 (Figure 2.3C).   
To compare our integrated gene set-based model with the single-gene level model 
previously described for this dataset[22], we tested our model in a validation dataset 
comprised of PBMC samples from a separate trial of TIV vaccination.  We found that our 
predictive model yielded an accuracy of 88% in the test set, comparable to the 
performance of the single-gene level predictor[22]. This indicates that gene set-based 
analysis of expression profiles provide accurate predictors of response to vaccination. 
 
2.2.4 Gene set-based predictors capture subtle alterations in gene expression profile. 
An advantage of a gene set enrichment analysis is that it can capture subtle 
changes in gene expression distributed across transcriptional networks. We therefore 
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compared the degree of differential expression of genes in the predictive gene sets 
(proliferation and immunoglobulin gene sets) with that of the genes selected in the single- 
Figure 2.4  Predictive gene sets capture genes with subtle changes in expression.   
Rank of genes identified in a single-gene predictor of TIV response (i), compared to the rank of genes contained in the 
proliferation (ii) and immunoglobulin (iii) gene-sets.  Each gene is indicated by a vertical line and its relative rank on 
the list of differentially expressed genes comparing TIV responders compared to non-responders is indicated by the line 
graph below. 
 
gene level predictor originally applied to this dataset (Figure 2.4).  Predictive genes 
selected in the study by Nakaya et al.[22] were all highly differentially expressed in Day 
7 PBMC expression profiles from responders compared to non-responders, as expected 
(mean fold change 3.36).  In contrast, the gene sets identified in our analysis included 
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many genes that were much less differentially expressed (mean fold change of 
proliferation cluster 2.13; mean fold change of immunoglobulin cluster 2.53) (Figure 
2.4).  
  
Figure 2.5 Enrichment of proliferation and immunoglobulin gene sets correlate with the frequency of 
antibody spot forming cells. (A and B)  
Enrichment scores of the proliferation gene set (A, 
CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP) and immunoglobulin gene set (B, 
REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT and frequency of IgG secreting cells (ASC). 
Significance is calculated by comparison to the null distribution, calculated by correlations derived from 
random gene sets.  
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Although the genes in the B cell and proliferation gene sets were enriched in 
respsonders, the majority of their constituent genes were not individually identified as 
significantly up-regulated in TIV responders in the previously published predictor (Figure 
2.4).  Indeed analysis of the functional annotations of genes in the previously published 
single-gene level predictor of influenza vaccine response[22] did not include terms 
related to B cell biology or proliferation. Thus a gene-set based approach can identify 
networks of predictive genes not otherwise detected by conventional, single-gene level 
approaches.   
2.2.5 The frequency of antibody producing cells correlates with the proliferation and 
antibody clusters. 
The simplest explanation for the predictive power of gene sets containing 
proliferation and antibody genes in individuals with high HAI response to vaccination is 
that it represents the increased frequency of proliferating B cells in post-vaccination 
samples. To test this hypothesis, we compared the frequency of antibody-producing B 
cells in the peripheral blood of vaccinated subjects at Day 7 post vaccination with the 
enrichment score for the top scoring proliferation and immunoglobulin clusters. 
We found that the enrichment score of both gene sets was correlated significantly 
with the frequency of IgG antibody spot-forming cells (ASC; Figure 2.5) but not IgM or 
IgA (Data not shown). This is most consistent with the interpretation that enrichment of 
these gene sets was caused by increased representation of proliferating plasmablasts in 
PBMC samples from vaccinated subjects with high antibody responses.   
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2.3 Methods 
2.3.1 Data preprocessing 
We analyzed two existing datasets of gene expression profiles of PBMC from 
vaccinated subjects: raw Affymetrix array data for subjects vaccinated with YF-17D from 
Gene Expression Omnibus (GEO) with the accession number GSE13486[9], and raw 
Affymetrix array data from subjects vaccinated with influenza TIV with accession 
number GSE29619[22]. The Genepattern module “CollapseDataset” was used to extract 
the expression values of genes from the raw data file and to map Affymetrix probes to 
gene symbols[26]. Then we applied quantile normalization and a log2 transformation. 
The final transformed data were used for the single sample GSEA projection (see below).  
For analysis of data from the influenza vaccinated subjects, gene expression fold change 
was calculated as the ratio of expression levels from PBMC profiles Day 7 (post-vaccine) 
/ Day 0 (pre-vaccine). 
2.3.2 Single sample gene set enrichment analysis (ssGSEA) 
GSEA yields a quantitative measure of the over representation of a set of genes S 
(e.g., genes encoding products in a same metabolic pathway) at the top or bottom of a 
ranked list of genes L. Candidate genes are ranked by their differential expression 
between two phenotypes. The statistic is a weighted Kolmogorov-Smirnov-like statistic 
and significance is calculated using an empirical permutation test[18]. Here we applied 
an extended version of conventional GSEA in order to produce an enrichment score on a 
per sample basis as we have previously[19]. Such a score is necessary if one is to make a 
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predictive call on single samples without reference to a larger group of samples. In this 
approach, the genes are ordered based on either absolute expression (as in the yellow 
fever vaccine study) or the relative changes with respect to the baseline level (as in the 
influenza TIV vaccine study).  
In this study, we used C2 collection from Molecular Signature Database 
(MsigDB). The MsigDB is a public available database of annotated gene sets hosted at 
Broad Institute (http://www.broadinstitute.org/gsea/msigdb/index.jsp)[16]. Currently 
there are 6 major collections from C1 to C6 while C2 is a special collection of gene sets 
carefully curated from online pathway databases, publications in PubMed, and 
knowledge of domain experts. Each of the ~3000 gene sets in C2 collection is well 
described in the MsigDB website including the source, annotation as well as other useful 
information, thus facilitate the interpretation of the biological meaning associated with it.  
2.3.3 Gene set feature selection 
To detect gene sets whose enrichment scores are highly correlated with 
phenotypes, we used an Normalized Mutual Information (NMI) score (Eq. (2.3)) to 
evaluate the association between phenotypes (Day 7 vs. Day 0 in the yellow fever 
vaccine study; or high vs. low HAI antibody response in the influenza TIV vaccine study) 
and gene set enrichment scores.  
 
Entropy: 𝐻 𝑥 =    𝑃 𝑥 𝑙𝑜𝑔!𝑃 𝑥 𝑑𝑥   (2.1) 
Mutual Information: 𝑀𝐼 𝑥, 𝑦 =    𝑃 𝑥, 𝑦 𝑙𝑜𝑔! 𝑃 𝑥, 𝑦𝑃 𝑥 𝑃 𝑦   𝑑𝑥𝑑𝑦     (2.2) 
	  	  
20 
Normalized Mutual Information: 𝑁𝑀𝐼 𝑥, 𝑦 =   𝑀𝐼(𝑥, 𝑦)𝐻(𝑥, 𝑦)        (2.3) 
Signed Normalized Mutual 
Information: 
𝑆𝑁𝑀𝐼 𝑥, 𝑦 =   𝑠𝑖𝑔𝑛 𝜌 𝑥, 𝑦 𝑁𝑀𝐼 𝑥, 𝑦    (2.4) 
Using mutual information to detect association is advantageous because it does 
not require assumptions about the distribution of samples (whereas e.g., t-statistic 
assumes a normal distribution of samples) and it allows the detection of non-linear 
associations (whereas Pearson correlation can only detect linear associations). Although 
the NMI scores do not inherently indicate positive or negative correlation, we used the 
sign of the Pearson correlation to decide the direction of the association and focus on 
positive associations in this study (Eq. (2.4)).  
 
2.3.4 Constellation Map  
Constellation Map is designed to visualize, and thus to elucidate, groups of gene 
sets enriched in a phenotype of interest (e.g., vaccine response) that correspond to distinct 
biological processes. The details of the implementation of Constellation Map as well as a 
Constellation Map web app will be described in Section 2.5 of this chapter. 
 
2.3.5 Protein-protein interaction (PPI) Construction and Module Detection 
We constructed the PPI network based on the InWeb database[24]. We identified 
the modules of the PPI network using the “FastCommunityMH” software package, a 
simulated annealing algorithm that optimizes the modularity of the network[27]. Here 
modularity measures the ratio between number of edges within modules and the number 
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of edges between modules. The optimized modularity indicates the best partition of the 
network that there are many edges within modules and only few between them.  
 
2.3.6 General linear model and Bayes’ rule 
We first built two logistic regression models using the best scoring gene sets from 
each of the two identified clusters of differentially enriched gene sets in TIV responders. 
The outcome of the logistic regression model is the probability that a sample belongs to 
the high response group given the enrichment score. We further combined the 
probabilities from these two models using Bayes’ rule as follows: for sample x with 
enrichment scores Ex1 and Ex2 for the gene sets used in the logistic regression model 
above and with corresponding probability of belonging to the high response group H, 
P(H | Ex1) and P(H | Ex2), we calculate the likelihood ratio that x belonging to the high 
response group as shown in Eq. (2.6).  
 
 
2.4 Discussion 
In this study, we applied a gene set enrichment-based approach to developing 
predictors of vaccine outcome and showed that enrichment of signatures corresponding to 
proliferating B cells accurately segregate vaccine responders to TIV with an AUC of 0.94 
in a training set and an accuracy of 88% in a validation set. Our approach uses the 
differential enrichment of sets of biologically related genes rather than single genes as 
Likelihood Ratio:  𝑃 𝐻     𝐸!!,𝐸!!)𝑃 𝐿     𝐸!!,𝐸!!) = 𝑃 𝐻     𝐸!!)𝑃 𝐻     𝐸!!)𝑃 𝐿     𝐸!!)𝑃 𝐿     𝐸!!)      (2.6) 
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predictive features.  This allows subtle biological changes manifest over networks of 
genes to be captured in a way that conventional gene expression predictors do not 
because they focus on small numbers of highly differentially expressed genes.  
Rapid expansion of plasmablasts following influenza vaccination has been 
previously observed[28], and it is intuitive that the magnitude of the plasmablast response 
would correlate with the humoral response to vaccination. However even at their peak, 
proliferating plasmablasts represent only a tiny fraction of the cells present in the PBMC 
samples analyzed by microarray in this study. As result, although detailed analysis of 
gene expression data from influenza vaccinated subjects had revealed that genes related 
to B cell biology were related to the HAI response, the magnitude of change in these B 
cell genes was not sufficiently large for them to be incorporated into the previously 
published gene expression predictor[22] In contrast, our approach allows subtle changes 
in sets of coordinately expressed genes related to B cell biology and proliferation to 
function as a predictive model of vaccine outcome. 
Gene set enrichment analysis is ideally suited to identifying small but coordinated 
changes in gene expression in sets of biologically related genes[17], [18].  It has been 
used to identify biological processes such as metabolic changes[17] and signaling 
flux[29] that are evident across networks of genes but subtle at the level of individual 
gene expression. The ability to build predictive models from small but coordinated 
changes in transcriptional programs is particularly important for clinical applications such 
as the detection of a vaccine response in which the transcriptional signal in responders 
compared to non-responders small.  We therefore anticipate that this approach to gene 
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expression predictor development will be generally useful in clinical situations in which 
the difference in gene expression between outcome classes is limited. 
An advantage of gene set-based predictors is that their biological meaning is more 
transparent. While predictive features based on individual genes may contain important, 
novel information about the vaccine response, their mechanistic basis is not always 
obvious without additional experimental inquiry[10], [22]. Instead, we developed our 
predictive model from a library of well-annotated signatures derived from previously 
published microarray experiments and expert curation. Together with a novel analysis 
and visualization method—the constellation plot (Figures 2.1 and 2.2)—this allowed the 
predominant biological themes that correlated with vaccination to be readily identified.   
A theoretical concern with our method is that the biological processes involved in 
the vaccine response may not be represented in the compendium of signatures currently 
used in the analysis. However, our results suggest that at least some of the biological 
signatures that predict vaccine response—such as proliferation—are already present in 
the database of signatures used for this study. Moreover, because the method we used can 
draw on any collection of annotated gene sets, it can easily be extended to additional 
collections of gene sets.  For instance, we and others are developing libraries of modules 
or gene-sets specifically devoted to cellular states and perturbations in the immune 
system[25], [30], [31] which should increase the biological resolution of gene set 
predictors even further.  
Finally, knowledge-driven gene expression based predictors may allow translation 
of gene expression-based predictors to assays that are simpler and more robust than 
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measurement of transcript abundance for many genes.  Gene expression predictors have 
historically been limited by a lack of reproducibility between experiments[15], [32]. This 
is thought to be related to the high variance of individual gene measurements commonly 
seen in datasets of relatively few replicates. This variance results in discordance between 
lists of predictive genes even in high quality experiments.  Using a larger set of genes 
rather than a small number of genes may provide some degree of robustness lacking in 
single gene-level predictors. Indeed several platforms have now been developed[33], [34] 
that allow focused sets of genes to be profiled at high throughput and low cost.  
Moreover, because gene set-based predictors can identify not just predictive genes but 
predictive biologies this approach could overcome the limits of predicting clinical 
responses by measuring gene expression. For instance, our analysis shows that signatures 
associated with cellular proliferation are predictive of a protective antibody response. It 
would be relatively easy to translate this to a flow-cytometry based assay of cellular 
proliferation in PBMC using Ki67 staining, for example, that could rapidly be applied to 
many samples. In contrast, developing and validating a multi-gene predictive signature of 
unknown biological significance may prove to be more significantly more complex. Gene 
set-based predictors predicated on biological knowledge may therefore provide a 
sensitive, relevant and robust analysis of the human immune response. 
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2.5 Constellation Map 
2.5.1 Description of Constellation Map 
Constellation Map presents gene set enrichment results as a radial plot. Each node of the 
plot denotes a different gene set. Nodes closer to the origin (i.e., with shorter radial 
distance) are more highly associated with the phenotype in question. The angular 
distance between any node pair indicates how similar their respective gene sets’ 
enrichment profiles are. Connecting edges between nodes denote an overlap between 
member genes, while edge thickness captures the relative size of the overlap. This multi-
metric layout is also presented in a JavaScript-powered browser environment for 
interactive exploration. Investigators can quickly identify clusters of connected nodes, 
i.e., gene sets with similar enrichment patterns that may represent different aspects of the 
same biological process. Identified clusters may be further interrogated using the tool by 
selecting clusters, extracting overlapping genes, and querying these genes using a variety 
of functional annotation tools [16], [21], [35]. Constellation Map thus accelerates the 
biological interpretation of enrichment results by clarifying the relationships between 
high scoring gene sets and facilitating identification of relevant subgroups of genes. The 
infant version of Constellation Map has been applied to uncover gene sets that predict 
subjects’ responses to TIV as described above. Visualizing and annotating with 
Constellation Map was crucial to our identification of the predictive gene sets and their 
biology. 
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2.5.2 Advantage of Constellation Map 
Other visualization and interpretation tools have been developed over the last few 
years to address the challenge of downstream interpretation of enrichment results. Unlike 
some of these tools, which are designed to handle Gene Ontology (GO) or other 
hierarchically organized gene sets [36], [37], Constellation Map can also handle gene sets 
derived from larger, less structured collections, such as the pathways and experiment 
signatures found in the popular MSigDB collections 
(http://www.broadinstitute.org/msigdb). The network-based visualizer, Enrichment Map 
(EM)[38], is somewhat similar to Constellation Map in that it displays gene set 
enrichment  results using a network representation where nodes represent sets and edges 
represent gene overlap between sets. Yet EM networks require manual annotation. 
Moreover EM clusters gene sets based on member gene overlap, which ignores the 
possibility of gene sets having similar enrichment profiles despite little member gene 
overlap. Constellation Map, on the other hand, provides automatic annotation and takes 
similar enrichment profiles into account, providing this information to the investigator as 
an intuitive angular distance.  
2.5.3 Workflow & Methods 
A user begins the Constellation Map workflow by either (1) identifying a group of 
top-scoring gene sets using GSEA, or some other preferred enrichment analysis 
approach, and utilizing single sample gene set enrichment analysis (ssGSEA)[39] to 
project samples into the space of top-scoring gene sets or (2) directly projecting data into 
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the space of all gene sets of interest using ssGSEA and later choosing to display only 
those most associated with a phenotype (Figure. 2.6).  
 
Figure 2.6 Diagram depicting the Constellation Map workflow.  
Two options exist. Users may either (1) analyze their whole genome transcript expression data using a 
preferred analysis method (e.g., GSEA) to identify a group of top-scoring gene sets, project samples into 
the space of these top-scoring gene sets using ssGSEA, and visualize the results using Constellation Map or 
(2) directly project their data into the space of all gene sets of interest using ssGSEA and choose only a 
small group of these gene sets to display with Constellation Map. 
 
 
To quantify the association between the gene set enrichment scores obtained via 
ssGSEA and phenotypic classes, Constellation Map calculates a normalized mutual 
information (NMI) score (Eq. 2.3). We chose to use the NMI metric because it is 
independent of the sample distribution and more sensitive to nonlinear associations than 
the more commonly used correlation coefficients. As NMI is unidirectional, we use the 
sign of the Pearson correlation to distinguish between positive and negative associations 
(Eq. 2.4). 
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After calculating the NMI scores, gene sets that significantly associate with 
phenotypes of interest can be selected (using an FDR or NMI score cutoff) and projected 
onto a radial plot. A second set of NMI scores is calculated to estimate the similarity 
between the enrichment profiles of the N selected gene sets. NMI scores may be 
converted into a dissimilarity score, d = 1 − NMI, which is a true distance (metric) [40]. 
Constellation Map uses this property to construct an N-by-N distance matrix D 
containing the distances d between all pairs of gene sets. Constellation Map then projects 
the distance matrix onto a radial plot where the angle between two gene sets is 
proportional to their pairwise distance in D and the radial distance from a gene set to the 
origin indicates its association with respect to the phenotype (1 – NMI). The circular 
Constellation Map plot is built using the multidimensional scaling projection R package, 
“SMACOF” version 1.5-0 [41]. An angular distance matrix Δ is calculated by 
minimizing the objective function (Eq. 2.7), where δij is the angular distance and dij is 
the original distance (stored in D) between gene sets i and j. The gene sets are plotted as 
points distributed about the origin. Angular distance between two gene sets is determined 
from Δ and is proportional to the similarity of the gene sets’ enrichment profiles. Radial 
distance (i.e., distance to the origin) indicates the gene set’s association with respect to 
the phenotype (1 – NMI). 
Objective Function	   𝜎 𝑋 = (𝛿!" − 𝑑!")! (2.7) 
 
The final step of Constellation Map projection involves connecting nodes with 
edges where the thickness of each edge is proportional to the Jaccard index between two 
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gene sets. The Jaccard index is equal to the number of genes shared by two sets divided 
by the number of genes in their union. 
 
2.6 Contributions 
The original development of the Constellation map and the data analysis for this 
project were my work. Felix Wu helped with the implementation of the JavaScript 
version of the web application and co-wrote text of the manuscript, which appears in 
Section 2.5 above.
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CHAPTER 3 IMPUTING MALARIA TRANSCRIPTOME BASED ON 
60 LANDMARK GENES  
The work described in this chapter was published in Genome Medicine [42] and 
the text of Sections 3.1, 3.3, 3.4, 3.5 were excerpted from that publication. 
  
3.1 Background 
Malaria infections of humans are restricted to five species of the Plasmodium 
parasite, with high morbidity associated with three species and high mortality associated 
predominantly with Plasmodium falciparum. This parasite infects over 200 million and 
kills more than 600,000 people each year[43]. The P. falciparum genome contains over 
5000 genes; more than half of these genes encode hypothetical proteins, expanded 
families of genes that interact with the immune system, and conserved proteins of 
unknown function[44]. The rapid generation time of P. falciparum, where 1 parasite 
divides into 16 to 24 daughter parasites within 24 to 48 hours[45], requires an enormous 
devotion of energy to cell cycle replication. Additionally, this rapid development is 
precisely coordinated through expression states that are predictable within the in vitro 
setting over 48 hours. This predictability allows for perturbations of the parasite with 
drugs and other culture conditions, which can lead to genome-wide changes in gene 
expression[46]. 
When parasite gene expression from peripheral blood is examined during human 
infection, there are unique physiologies present that, as yet, cannot be replicated in 
vitro[47],[48]. Samples derived from human subjects are often precious, of small volume 
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(especially in the pediatric setting), collected on media not suitable for traditional RNA 
analysis (e.g., filter paper, formalin fixed paraffin embedded tissue) and, by definition, 
contaminated with human RNA. Furthermore, because parasites in the trophozoite and 
schizont stages sequester deep in endothelial tissues, these parasites are only accessible 
by tissue biopsy or autopsy. Previous studies with autopsy tissues have measured parasite 
gene expression using quantitative real-time PCR (qPCR)[49]. Low parasite RNA 
abundance, poor quality, and the presence of human RNA of tissue-sequestered parasites 
have made approaches to measure malaria gene expression in the genome-wide scale 
inaccessible to date. 
In this project we applied two new techniques to measure gene expression of 
malaria parasites sequestered in patient tissues. Using a set of nCounter malaria gene 
probes, we quantified malaria gene expression in vivo, first in a validation set of 
peripheral blood samples and subsequently in a set of malaria-infected human tissue 
samples collected at autopsy. We also used whole-genome imputation to generate 
genome-wide transcriptional profiles for each sample, providing a first look at the gene 
expression profiles of in vivo sequestered malaria parasites.  
 
3.2 NanoString nCounter Platform 
The NanoString nCounter platform is a medium-throughput approach to detecting 
and quantifying mRNA in a complex mixture.[50] In this system, two probes—a capture 
probe and a reporter probe—are used to capture and count the number of copies of each 
mRNA molecule. The capture probe contains a 35- to 50-base sequence complementary 
to a particular target mRNA plus a short common sequence coupled to an affinity tag 
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such as biotin. The reporter probe also contains a 35- to 50-base sequence complementary 
to the target mRNA, which is coupled to a color-coded tag that provides the detection 
signal (Figure 3.1A). For each gene of interest, a unique pair of capture and reporter 
probes is used to detect its transcripts. Sample preparation involves mixing total RNA 
together with probes in a single hybridization reaction. This procedure results in the 
formation of tripartite structures, each comprised of a target mRNA bound to its specific 
reporter and capture probes. Unbound probes and mRNA are washed away. 
 
Figure 3.1 Overview of NanoString nCounter gene expression system. Geisis et. al. 2008 
 
The bound complexes are then placed on a surface embedded with a capture reagent. An 
electric field applied to the surface extends and orients each complex in the solution in 
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the same direction (Figure 3.1B). Each target mRNA is subsequently detected and 
counted via the color code generated by the ordered fluorescent segments present on the 
reporter probe (Figure 3.1C). 
The nCounter platform is capable of measuring gene expression with accuracy 
similar to qPCR, yet requires significantly less preparatory work, is highly automated, 
and is capable of measuring expression in crude cell lysates. Importantly, there is no use 
of reverse transcription or amplification methods prior to measurement, eliminating 
amplification bias. However, The nCounter platform this system can only support the 
acquisition of 524 probes (15 controls and 509 genes).. Thus, the challenge presented is 
to find a way to obtain the full transcriptome of P. falciparum from a much smaller 
number of gene expression levels. 
 
3.3 Experimental Design and Data Analysis  
 
3.3.1 Probe set design, sample preparation and patient samples 
Details of probe set design, sample preparation and patient samples are described in [42].  
3.3.2 Whole-genome imputation  
The NanoString nCounter platform is a medium-throughput technology, which 
can only yield a gene expression profile of a few hundred genes. In order to obtain P. 
falciparum gene expression profiles on a genome-wide scale, we adopted a whole-
genome expression imputation approach. Using a small subset of “landmark” genes 
measured on the nCounter platform, we impute the expression profiles of the rest of the 
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genes in the genome. This imputation algorithm was originally developed by Donner et 
al.[5] for use on  human gene expression data on Affymetrix platform. 
The Affymetrix compendium described above was curated and filtered for genes 
that were present in all data sets, as well as genes that varied in their expression across 
data sets. This filtered list of 3,696 genes was used as a training dataset to select a subset 
of probes, called landmarks, and generate the imputation model. Specifically, we used the 
Regularized Gaussian Estimation (RGE) method proposed by Donner et al., whereby the 
expression of the complete probe set is modeled as a Gaussian distribution over full 
expression profiles using the training data. Landmarks were selected to minimize the 
prediction error in the model. Imputation involved computing the conditional expected 
value of the unobserved genes given the observed genes in the Gaussian model. To 
decide the optimal number of landmark probes required to impute the full expression 
profile of each sample, we computed the model fitting errors of models using between 10 
and 100 probes. We found that an imputation model using 60 landmarks was ideal, since 
including additional probes into the model beyond 60 did not yield a large improvement 
in imputation accuracy (Figure 3.2A).  
3.3.3 Differential gene expression  
Imputed nCounter gene expression for three patients with three different organs 
sampled was analyzed to determine parasite genes that are overexpressed in vivo. The 
three samples from each patient were compared with 11 in vitro microarray time points 
with highest correlation[51]. Because of differences across platforms, both in vitro and in 
vivo expression data were converted to ranks and coerced into a range of 1 to 10,000. 
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Differential gene expression analysis was conducted using the Limma R package 
produced by the Bioconductor project [52]. Limma is widely used for differential 
expression analysis of data arising from microarray experiments. Briefly, the method fits 
a linear model to the expression data for each gene and uses an empirical Bayes approach 
to borrow information across genes, which is equivalent to shrinking the estimated 
sample variances towards a pooled estimate, thus making the analyses robust even when 
the sample size is small.  
3.3.4 Statistical analysis  
The nCounter® platform raw data were normalized with the NanoStringNorm R 
package[53], using the arithmetic mean to summarize negative and positive controls. We 
also checked the diagnostic messages from NanoStringNorm, and confirmed that all of 
the samples had normalization factors within the range of three standard deviations from 
the mean. Expression analyses were based on rank normalized data, in order to avoid 
systematic variations between data sets due to differing amounts of input malaria mRNA. 
We used Spearman’s rank correlation coefficient to make comparisons between nCounter 
and both Affymetrix and two-dye microarray data. To assess the relative importance of 
the differential gene expression results, genes were ranked by log-fold change, from 
largest to smallest. The top 100 overexpressed genes in each patient were compared, and 
39 genes shared between all three patients are summarized in Table 3.1.  
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3.4 Results 
3.4.1 Whole-genome expression imputation 
I used imputation to calculate expression values for unknown genes using a small set of 
pre-defined genes. The method was validated against parallel Affymetrix microarray 
data[54], and revealed that imputation based on 60 landmark genes could accurately 
approximate global transcriptional patterns, with minimal improvement in accuracy for 
imputation from more than 60 genes (Figure 3.2A). Imputed gene expression from 52 
peripheral blood samples measured with the nCounter platform showed good correlation 
with genome-wide Affymetrix microarray data gathered from the same samples (Figure 
3.2B). To examine the accuracy of imputation on a gene-by-gene basis, we examined 
median differences in rank abundance (Figure 3.2C), and average Pearson correlation 
(Figure 3.2D), between imputed (from nCounter) and observed (Affymetrix) expression 
of each gene among the 52 peripheral blood samples. Approximately 65% of imputed 
genes had a median difference in rank abundance lower than 500 (Figure 3.2C), and 
roughly 70% of genes had an average Pearson correlation above 0.3 (Figure 3.2D). 
Finally, the strength of correlation between imputed and observed values scaled with 
gene expression (Figure 3.2E), with more highly expressed genes having higher 
correlations and more lowly expressed genes having lower correlations. 
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Figure 3.2 Imputation of global expression profiles based on landmark P. falciparum genes. 
(A) Model fitting. Spearman rank correlations between imputed and observed gene expression for 3,696 genes, based 
on imputation from varying numbers of probes. (B) Model testing. Spearman rank correlations between imputed and 
observed gene expression in 52 peripheral blood RNA samples, measured with both Affymetrix microarrays and 
nCounter®, before and after imputation. IAvA: imputed Affy vs. Affy (n = 3,969 genes); NvA: nCounter® vs. Affy (n 
= 328 genes); INvA: imputed nCounter® vs. Affy (n = 3,696 genes). (C) Cumulative distribution of median differences 
in rank abundance for 3,696 genes between gene expression imputed from nCounter® versus Affy, averaged over 52 
peripheral blood RNA samples. (D) Cumulative distribution of Pearson correlations between imputed and measured 
gene expression, averaged over 52 peripheral blood RNA samples. (E) Correlation between imputed and observed gene 
expression scales with expression level. Pearson correlation versus quantile-normalized and log2-transformed gene 
expression for 3,696 genes averaged over 52 peripheral blood RNA samples. 
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Figure 3.3 In vivo parasite gene expression clusters by patient rather than by organ. 
(A) Hierarchical clustering of expression of 328 genes measured by nCounter® from 13 tissue samples collected at 
autopsy, collected from five patients and three organs. Clustering demonstrates that samples cluster by patient, rather 
than by organ, suggesting that parasite physiology within a patient is conserved. (B) Hierarchical clustering of global 
expression profiles imputed from nCounter® (n = 3,696 genes) shows that within-patient clusters remain intact. Note 
that two outliers in the first analysis (P1, Brain and P2, Heart) are further delineated as true outliers after imputation. 	  
3.4.2 Differential expression analysis on imputed whole genome expression  
We used the nCounter® platform and global imputation to ask whether in vivoin 
vivo parasite samples cluster by organ or by patient (Figure 3.4), and to detect genes that 
are overexpressed by parasites sequestered in human tissues (Table 3.1). Hierarchical 
clustering of in vivo sequestered parasites from autopsy tissue samples showed that 
samples cluster by patient, rather than by organ, regardless of whether clustering is based 
on gene expression measured by the nCounter platform (Figure 3.4A), or imputed gene 
A B 
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expression (Figure 3.4B). Differential gene expression analysis between rank-normalized 
imputed in vivo and in vitro microarray data revealed a shared set of 39 genes that were 
among the top 100 overexpressed genes in all three of the analyzed patients (Table 3.1).  
This set of in vivo overexpressed genes included ten genes with maximal expression 
during sexual and mosquito stages, 10 genes with maximal in vitro expression during 
trophozoite and schizont stages, 7 genes that are not expressed in vitro, and 6 genes that 
code for ribosomal proteins. These data indicate that parasites sequestered in human 
tissues may exist in a unique physiological state.  
 
3.5 Discussion 
The development of new tools and adaptation of existing tools for use by malaria 
researchers and clinicians to meet elimination and eradication goals is a priority. Ideal 
tools should yield maximal information from minimal amounts of biological sample, and 
be both affordable and easy to use. Our goal is to develop and deploy such tools for 
global use by the malaria community. In this project we show how adaptation of two 
existing tools—the nCounter platform and imputation of global gene expression—can be 
leveraged to uncover the expression profiles of in vivo sequestered malaria parasites. 
These unique transcriptional profiles have, until now, been impossible to measure on a 
global scale. 
Because both human [55] and malaria parasite [47], [48], [54], [56] physiologic 
expression states are predictable, they can be accurately determined using subsets of 
carefully selected landmark genes. Full-scale prediction of global expression profiles 
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using established imputation methods allowed us to query the expression of nearly 3,700 
genes from just 60 landmarks. When we compared imputed expression profiles with 
expression data from the same RNA samples measured with microarrays, we found that 
correlations between imputed and observed expression were only slightly lower than 
cross-platform correlations performed without imputation (Figure 3.2 B). Nonetheless, 
genes that were lowly expressed in all samples showed poor correlations between 
imputed and observed expression across the 52 samples we used to test the imputation 
model (Figure 3.2E). Additional data from further studies of parasite physiology will be 
useful for refining the imputation model to incorporate additional variation and more 
accurately impute lowly expressed genes. 
Previous studies have applied nCounter to other infectious diseases [57]–[59]; 
however, this is the first application to measure malaria parasite physiological states in 
vivo. We found that parasites sequestered in human tissue overexpress genes that are 
enriched during gametocyte and mosquito stages, as well as genes that are not normally 
expressed in vitro. Importantly, many of the shared overexpressed in vivo genes encode 
conserved proteins of unknown function, indicating unexplored areas of parasite 
physiology that are relevant in vivo. Using additional data sets and collaborations with 
others in the malaria research community, future custom nCounter arrays can be designed 
to study specific gene sets, at costs comparable to qPCR but with massive savings of both 
time and throughput. 
 
 
	  	  
41 
Table 3.1. Summary of shared malaria genes overexpressed in three in vivo patient samples1 
Category Number Description2 Gene Names 
Gametocyte/
Mosquito 10 
Maximal expression during 
gametocyte or mosquito stages 
PFA0425c, PFC0581w, PFC0755c, 
MAL7P1.64, MAL7P1.109, 
PF10_0169, PF10_0204, PF11_0163, 
PF13_0350, PF14_0031 
Trophozoite/ 
Schizont 10 
Maximal in vitro expression 
during late trophozoite or 
schizont stage 
PFA0210c, PFI0810c, PFI1445w, 
PF10_0268, PF10_0330, PF11_0048, 
PF11_0156, PF11_0183, PFL1565c, 
PF14_0366 
In vivo 
expressed 7 
Genes with less than 100 
RPKM3 for any stage in vitro 
PFC0005w, PFI1600w, PFI1830c, 
PF11_0203, PFL1010c, PFL1195w, 
PF14_0363 
Ribosomal 6 Ribosomal or putative ribosomal proteins 
PFC0535w, PF11_0043, PF11_0106, 
PF13_0171, PF13_0213, PF14_0027 
Other 6 
Maximal expression during 
ring/early trophozoite stage, or 
conflicting stage data 
PFE1370w, PF11_0111, PF11_0224, 
PF14_0277, PF14_0359, PF14_0437 
1 Three parasite samples from each of three patients were compared with 11 in vitro microarray time points 
with highest correlation to each patient.  
2 Life cycle stages of maximal expression were assigned based on microarray and RNAseq data available 
from PlasmoDB.org 
3 RPKM = reads per kilobase per million mapped reads 
 
3.6 Contributions 
In this project I conducted the landmark selection using the method developed in 
[5], preprocessing of expression data obtained from nCounter platform, statistical 
analysis of imputed whole-genome expression and extraction of differentially expressed 
genes. 
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CHAPTER 4 LEADING EDGE METAGENE DETECTION 
The work described in this chapter is excerpted from a manuscript I co-authored 
with Jernej Godec, entitled “Identifying convergent patterns of vaccine-induced changes 
in gene expression by reducing the dimensionality of gene-set enrichment analysis 
results”. That manuscript will be submitted to the journal PLoS Computational Biology at 
the second quarter of 2015. 	  
4.1 Introduction 
Changes in the state of a cell or tissue are often reflected in the alterations of large 
numbers of genes. Analysis of large-scale datasets from yeast[60] to humans[61]  
demonstrates that changes in gene expression accompanying a biological shift in the cell 
state are organized into “modules” or sets of genes that play a functional role in executing 
a particular biological process. However, many changes of gene expression in many 
transcripts in such modules are of such small magnitude that they would be hard to detect 
over experimental noise when considered individually[17], [62]. As a result, several 
computational tools have been developed to detect the coordinate up-regulation of a 
program of genes [63] with robust statistical measures, even though the absolute change 
in expression of any constituent gene in the set of genes may be small. 
One widely-used approach is gene set enrichment analysis (GSEA)[18], which 
tests whether a set of genes of interest are randomly distributed throughout a rank-
ordered list of genes (usually generated by comparison of the gene expression profiles of 
two phenotypic classes) or over-represented at the top or bottom of the list. The latter 
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finding then leads to the inference that this set of genes is related to the underlying 
biology of the two phenotypes in question. The power of GSEA and other analytic 
enrichment tools to yield insights into biology is critically dependent on the number and 
quality of databases of sets of genes, which are tested for enrichment in the phenotypic 
comparison of interest. Some databases, like Gene Ontology [64] or TRANSFAC [65] 
represent collections of genes generated a priori, without reference to specific 
experiments. Others, such as MSigDB [20] include a large numbers of gene sets curated 
from experimentally derived expression profiles corresponding to cell states and 
perturbations.  
However, the increase in the number of gene sets that become available for 
analysis can lead to the need for downstream analysis for the interpretation of GSEA 
results. The first challenge arises when a list of enriched gene sets contains considerable 
redundancy, i.e. multiple gene sets with a subset of genes in common. For instance, 
results of GSEA may contain multiple gene sets each of which contains a signature of 
genes corresponding to a common biological process such as proliferation or interferon 
response, even though the experiments that elicited proliferation or interferon response 
were quite distinct. While the annotation of the gene sets themselves can provide 
considerable biological insight, it may not be immediately apparent whether the 
enrichment of two or more gene sets is due to the presence of the same set of genes in 
multiple gene sets that “explains” their enrichment. 
A second challenge is that as increasing numbers of gene sets become available 
for use with GSEA the results of an analysis can often include tens or hundreds of 
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significantly enriched gene sets requiring considerable investigator review. Tools that 
reduce the dimensionality of GSEA results, and that could identify coordinately up-
regulated sub-signatures contained within several enriched gene sets which correspond to 
the biology themes present in the phenotypic comparison of interest would be useful 
adjunct to the interpretation of GSEA results. 
To address these problems, we have developed an analysis approach to identify 
modules of genes which we term “leading edge metagenes” (LEM) that are both common 
to multiple, significantly enriched gene sets, and coordinately enriched in a phenotypic 
comparison of interest. We show that the metagenes are more significantly enriched for 
biologically related genes than the parent gene sets or their leading edges. The leading 
edge of a gene set consists of those genes that “drive” the enrichment score in a GSEA 
analysis (see Methods in section 4.3). We apply this approach to the analysis of the 
transcriptional response induced by five different vaccines measured in peripheral blood 
mononuclear cells (PBMC). By examining the results of a GSEA analysis in the space of 
the LEM, we can more clearly see that different vaccines initially elicit distinct, 
biologically coherent patterns of gene expression three days after vaccination, but these 
transcriptional patterns of response become more similar with increasing time after 
vaccination. 
4.2 Results 
4.2.1 Overview of the leading edge metagene method 
We developed an approach to identify groups of genes – termed leading edge 
metagenes – that are both associated with a phenotype of interest, and shared between 
	  	  
45 
multiple gene sets enriched in that phenotypic comparison. We reasoned that groups of 
genes that are co-regulated in the phenotype of interest and also present in multiple gene 
sets are likely to represent the core modules of genes related to distinct biological 
processes or pathways. Our approach leverages the notion of the leading edge genes in a 
GSEA analysis, which are the genes whose expression profile is most highly correlated 
with the phenotype distinction in a comparison of biological states and thus drives the 
GSEA enrichment statistic. We present here an overview of the leading edge metagene 
(LEM) method that is summarized in Figure 4.1, and give more detail in Methods. 
Step 1: Employ GSEA to identify the enriched gene sets in a phenotypic 
comparison of interest, such as gene expression profiles of PBMC samples before and 
after vaccination.  Extract the leading edge genes from each enriched gene set. 
 Step 2:  Construct a sparse m by n matrix M of genes by gene sets.  The entries in 
each column give corresponding leading edge gene’s correlation with the phenotype 
distinction in the data set.  Note that if a gene is not in the gene set’s leading edge its 
entry will be 0. 
 Step 3:  Apply nonnegative matrix factorization (NMF)[66] to M.  This will yield 
a product of two matrices W x H that approximates M, where the entries of the columns 
of W indicate the contribution of each gene to the corresponding metagene and the H 
matrix represents the gene sets in the space of metagenes.   
 Step 4:  We next filter the metagenes, or columns of the matrix W, i.e., we set to 0 
the entries that are sufficiently small.  Note this has the effect of removing the 
corresponding gene from that metagene. 
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 Step 5:  Finally we define the leading edge metagenes for each column in the W 
matrix as follows: each gene with non-zero entries in its row is assigned to the leading 
edge metagene with the largest coefficient. 
Figure 4.1 Schema of leading edge metagene analysis. 
4.2.2 Gene set enrichment analysis of the transcriptional response to YFV vaccination. 
We applied this approach to the gene set enrichment analysis of the transcriptional 
response to vaccination. Transcriptional profiling of the vaccine response has been used 
to identify biological processes associated with different vaccines and to develop 
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predictors of protective immunity following vaccination[22], [67], [68]. The changes in 
gene expression in PBMC following yellow fever vaccine (YFV) vaccination of healthy 
volunteers have been well-studied[10], [53], and provided a useful test case in which to 
apply leading edge metagene analysis. We studied a dataset of gene expression profiles of 
PBMC from healthy volunteers (n = 15) either before (day 0) or after (day 7) vaccination 
with YFV-17D, a live attenuated viral vaccine. We ranked genes by their differential 
Figure 4.2 GSEA of the transcription response to YFV vaccination identifies leading edge genes. (A)  
GSEA of genes up-regulated in PBMC after YFV vaccination in healthy volunteers using the C7 Immune Signatures 
Database. The top 20 most enriched gene sets are shown as rows of “barcodes” with lines representing the position of 
each gene on the ranked list of genes differentially expressed post- vs. pre-vaccine (X-axis). Leading edge genes (red) 
are those that occur before the maximal enrichment score for each gene set. (B) Frequency histogram of the number of 
leading edge genes co-occurring in multiple gene sets. 
 
expression in day 7 vs. day 0 and performed GSEA using the Immune Signatures 
collection of MSigDB, a compendium of almost ~ 2,000 signatures curated from 
experimentally derived gene expression profiles in the immunology literature (manuscript 
in preparation). We identified 481 gene sets that were significantly enriched at day 7 
following YFV vaccination relative to day 0 (Figure 4.2A). Many of the enriched gene 
sets were those that would be expected to correlate with vaccination-induced changes in 
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gene expression, such as those related to inflammation, cell proliferation, and response to 
virus. 
We extracted the leading edge genes from all 481 enriched gene sets and assessed 
the frequency of co-occurrence of genes in gene sets (Figure 4.2B). Of the 2821 leading 
edge genes present in any of the enriched gene sets, the vast majority (75%) were present 
in 10 or fewer gene sets, and the resulting matrix of gene sets and leading edge genes was 
sparse with 98% of the entries are 0. 
 
Figure 4.3 LEM analysis identifies three leading edge metagenes in the transcriptional response to 
YFV vaccination.  
(A) Consensus cluster matrix for gene sets membership values averaged from 100 matrices using 2821 
leading edge genes from 482 gene sets enriched in day 7 post-YFV profiles compared to pre-vaccine 
profiles computed at k = 3. Red values are highly correlated; blue uncorrelated. (B) Coefficients of the 
contribution of each leading edge gene to the three clusters of genes identified in (A). Dotted red line shows 
the threshold of 1, which is 95 quantile based on a fitted exponential distribution. (C) Heat map of the 
coefficients (post vs. pre vaccine) of genes assigned to each of three metagenes present in the YFV vaccine 
signature. Representative genes indicated on the right. 
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4.2.3 Identifying leading edge metagenes in the transcriptional response to YFV 
vaccination 
We then applied NMF consensus clustering to estimate the number of clusters in 
the leading edge sparse matrix. As is suggested by the consensus matrix in Figure 4.3A, 
there are three clusters in the leading edge sparse matrix, indicating that a W matrix with 
rank of 3 is the best low dimensional approximation of the original leading edge sparse 
matrix. A simple inspection of coefficients in each of the columns in the rank 3 W matrix 
suggests that most genes have very small coefficients and only a small fraction of genes 
have significantly large coefficients (Figure 4.3B). To filter out genes with negligible 
contributions to metagenes, we fitted three exponential distributions to each of the three 
metagenes in the W matrix. As is shown in Figure 4.3B, genes with coefficients below the 
cutoff of 1 (colored white) are filtered from the W matrix while rest of the genes (red 
color gradient) are assigned into one of the three metagenes based on the procedures 
described in Methods. 
4.3.4 Leading edge metagenes are highly enriched for genes associated with biological 
processes 
We reasoned that genes contained in leading edge metagenes would be a more 
refined list of biologically related genes than those in the gene sets from which they were 
extracted. Experimentally derived gene sets are generated from the comparison of two 
phenotypic classes, and as such are likely to entrain genes related to multiple, different 
biological processes and a variable degree of experimental noise. In contrast, leading 
edge metagenes, are “filtered” by virtue of appearing at the leading edge of enrichment in 
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a phenotype of interest (here, day 7 post-vaccination) of multiple experimentally-derived 
gene sets. We therefore tested whether leading edge metagenes were more highly 
enriched for genes related to biological processes (as annotated by Gene Ontology) than 
their parental gene sets (Figure 4.4). We tested the set of 3 leading edge metagenes for 
overlap with the collection of GO annotated gene lists, and determined the significance of 
each GO term’s overlap. We compared the P values generated by GO term overlap with 
metagene genes with an equivalent number of genes randomly sampled from the original 
pool of leading edge genes, or from all genes in the genome. We found that the 
significance of GO term overlap was much higher in the leading edge metagenes than in  
Figure 4.4 Leading edge metagenes are more enriched for biological signatures than the unrefined set of leading 
edge genes.  
Violin plots of the distribution of –log10 hypergeometric P values calculated from overlap of GO term-annotated genes 
with LEMs (right), randomly selected groups of genes of similar size from the leading edges (middle) of enriched gene 
sets, or the whole-genome (left). Black dots represent the –10 * log10 P value for GO terms that enrich with a P value < 
1e-5. 
 
the original leading edge genes or in a random set of genes. GO terms that were enriched 
included many with known roles in the vaccine response to attenuated viral vaccines 
including those related to virus response, cytokine production and proliferation. LEM 
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analysis therefore provides an effective approach to enrich GSEA results for the sub-set 
of genes most related to the biology of interest. 
 
Figure 4.5 Comparison of leading edge metagenes elicited three and seven days after vaccination by five 
vaccines.  
Circos plots indicating overlap in gene membership of metagenes elicited by five vaccines (indicated in the box at the 
center of the plot) on Day 3 (grey band) vs. Day 7 (black band) post-vaccination. Breadth of the connecting ribbon is 
proportional to the fraction of genes shared between metagenes. The predominant biological process present in each 
arbitrarily-numbered metagene is indicated in text beside each segment. 
 
4.2.5 LEM analysis identifies conservation and divergence of biologic kinetics in human 
vaccines 
We extended LEM analysis to an additional four previously published datasets of 
gene expression profiles from PBMC following vaccination[67]. The vaccines studied 
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differed in immunogens and adjuvant, mechanism of action, and targeted disease. They 
included both polysaccharide and conjugate vaccines targeting meningococcal disease 
(MPSV4 and MCV4, respectively), trivalent influenza vaccine (TIV) and live attenuated 
virus vaccines targeting influenza (LAIV).  
For each vaccine, we compared the transcriptional response at day 3 or at day 7 
post-vaccination to the baseline time point at day 0 prior to vaccination. We identified 
significantly enriched gene sets in the post-vaccination samples using the C7 Immune 
Signatures collection from MSigDB and extracted metagenes associated with the vaccine 
response for each vaccine at both time points. Initial GSEA results returned between 0 
and 550 gene sets that were significantly enriched in each of the post-vaccination datasets 
relative to pre-vaccination samples. LEM analysis reduced these large collections of gene 
sets to three metagenes in each vaccination at each time point. We annotated this set of 
fifteen metagenes using Gene Ontology (GO) Terms based on the strongest overlap of a 
metagene with one of the ten representative GO Terms (Figure 4.5) identified by 
REVIGO[64], [69]. We identified metagenes related to biological processes that have 
previously been shown to be involved in the PBMC transcriptional response to 
vaccination. For instance, we found that metagenes that include genes related to cell 
cycle, immune response, and response to virus and stress were present in several vaccines 
and at different time points. This is consistent with previous reports that found similar 
biology to be important in vaccine-induced responses [10], [22], [68], [70], [71]. 
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We next compared the metagenes that were identified at day 3 post-vaccination to 
those found at day 7 for each vaccine by comparing the fraction of shared genes in each 
metagene. We found that the degree of overlap of metagenes at day 3 and day 7 varied 
widely in different vaccines (Figure 4.5). For instance, the transcriptional response to 
MCV4 at day 3 induced metagenes that had minimal overlap with genes in metagenes at 
day 7. However, the closely related vaccine, MPSV4 showed a striking overlap in the 
metagenes between day 3 and day 7. In the case of TIV, a metagene representing cell 
cycle progression was evident at both day 3 and day 7, whereas metagenes related to 
intracellular transport and immune response observed at day 3 showed minimal overlap 
with metagenes found at day 7 in the same vaccine. This suggests that while proliferation 
is a prominent part of the transcriptional response to TIV at day 3 and day 7, other 
transcriptional features shifted in this time frame. This contrasts with the metagenes 
elicited by vaccination with LAIV, which showed no evidence of proliferation until day 
7. This is potentially related to the fact that TIV is administered intramuscularly and thus 
may elicit a more rapid response when measured in the blood than LAIV, which is given 
intranasal route. 
4.2.6 Diverse vaccines elicit distinct transcriptional responses at day 3 but become more 
similar at day 7 
The vaccines examined vary in their composition and include live attenuated viral 
vaccines (YFV and LAIV), inactivated virus (TIV), carbohydrate (MPSV4) and 
polysaccharide-conjugate (MCV4). We therefore examined the shared and unique 
metagenes induced by different vaccines at day 3 and at day 7 post-vaccination. We 
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computed the significance of each pairwise overlap of metagene membership using a 
hypergeometric test, and visualized these comparisons as a heat map (Figure 4.6A).  
Figure 4.6 The transcriptional response in five different vaccines becomes more similar over time.  
(A) Pairwise overlap of metagenes elicited by five vaccines on Day 3 post-vaccine (left) or on Day 7 post-vaccine 
(right). Heat map values correspond to the significance of the overlap (shown as –log10 hypergeometric P values). Each 
metagene is given an arbitrary number, and the predominant biological process present in each metagene is indicated 
by the color key. (B) Hierarchical clustering of vaccines calculated by similarities in the significance of metagene 
overlap at Day 3 post-vaccine (left) or on Day 7 post-vaccine (right).  
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overlap, possibly suggesting different mechanisms or kinetics of cell cycle progression 
induced by these different vaccines. In contrast, neither meningococcal vaccine showed 
significant overlap with any of the metagenes elicited by viral vaccines. However, there 
was significant overlap in the metagenes elicited by the inactivated and live attenuate 
viral vaccines including metagenes related to cell cycle, intracellular transport, and the 
immune response. We visualized the relative distance between these overlaps using 
hierarchical clustering and found that the meningococcal vaccines clustered on a distinct 
branch of the dendrogram to the viral vaccines (Figure 4.6B, left). 
At day 7, however, we observed a much broader degree of overlap between 
metagenes induced by different types of vaccines. In contrast to day 3, we found that 
multiple metagenes elicited by meningococcal protein vaccines showed similarity to 
those elicited by viral vaccines. For instance, the proliferation metagene induced by YFV 
(live attenuated vaccine) showed significant similarity to the proliferation metagene 
elicited by MPSV4 (P=8.65x10-6), MCV4 (P=6.65 x10-8), as well as to LAIV (P=2.2x10-
5) and TIV (P=9.16x10-6). Similarly an immune response and protein-folding metagene 
elicited by MCV4 showed significant overlap with metagenes elicited by TIV and YFV. 
Moreover, hierarchical clustering showed much closer degrees of relatedness between all 
five vaccines than was seen at day 3 (Figure 4.6B, right). Thus the patterns of metagene 
expression elicited by carbohydrate and protein conjugate vaccines are distinct from 
those elicited by viral vaccines at day 3, but become more similar at day 7.	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4.3 Methods 
4.3.1 Overview 
The goal of the LEM algorithm is to identify component biological sub-signatures 
among a group of gene sets that are enriched in a phenotypic comparison of interest. This 
algorithm starts with n significantly enriched gene sets from a GSEA analysis and yields 
a small group of gene subsets, the leading edge metagenes, which capture the biological 
processes differentially present in the phenotypic comparison. There are 5 key elements 
in this method as follows. 
 
Step 1: Identify enriched gene sets and their leading edges 
We first identify gene sets that are enriched in a phenotypic comparison of 
interest, such as gene expression profiles of PBMC samples before and after vaccination. 
GSEA has been extensively described [6] and typically queries a list of genes ranked by 
their differential expression in two phenotypes with gene sets from databases such as 
MSigDB[20]. GSEA calculates an enrichment score (ES) that reflects the degree to 
which a set of genes is overrepresented at the extremes (top or bottom) of the ranked list. 
The statistical significance of this overrepresentation is estimated using an empirical 
phenotype-based permutation test[6]. Enriched gene sets are considered to be those that 
exceed a statistical threshold (e.g., false discovery rate) set by the user, and can, in typical 
experiments, include dozens or even hundreds of gene sets. The leading edge subset of 
genes in an enriched gene set are defined as those which appear in the ranked list before 
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the point at which the running sum of the ES is greatest. Leading edge genes therefore 
represent the most enriched subset of genes in a gene set. 
 
Step 2: Construct leading edge sparse matrix 
We then consolidate the leading edges of the n top-scoring gene sets into an n-by-
m sparse matrix M, where the columns represent the m genes in the union of all the 
leading edges of a group of enriched gene sets and the rows represent the n enriched gene 
sets. The value of each entry in the matrix is the signal to noise ratio of the corresponding 
gene between two conditions in comparison (Eq. (4.1)) A large signal to noise ratio 
indicates a significant difference in expressions of the corresponding genes between the 
two conditions. 𝑠2𝑛 = 𝜇! − 𝜇!𝜎! − 𝜎!  (4.1) 
 
Step 3: Estimate number of clusters in leading edge sparse matrix through NMF 
We use non-negative matrix factorization (NMF) to cluster the sparse matrix in 
order to identify clusters of genes with a similar pattern of leading edge membership in 
multiple gene sets and up- or down-regulation in the phenotype of interest. NMF is an 
efficient method for identifying hidden structures within data[72]. Here we use NMF 
coupled with a model selection mechanism to estimate the number of clusters within the 
leading edge sparse matrix. Specifically, for a given leading edge sparse matrix M with n 
rows and m columns, we can approximate the original gene sets as positive linear 
combinations of these metagenes. The described procedure is equivalent to factorizing 
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the leading edge sparse matrix M into two matrices such that 𝑀 ≈𝑊×𝐻[66], [73]. The 
W matrix is a low-dimensional (rank k and k << m) representation of the M matrix and 
each dimension of W is a positive linear combination of n genes, a metagene. The entries 
in the W matrix represent the contributions of each gene to the metagene and the entries 
in the H matrix represent the amount of each metagene required to recapitulate the gene 
expression profile in each of the m gene sets. Determining the rank k of the W matrix that 
best approximates the original leading edge sparse matrix is a key issue. To find the best 
rank k, we adopted a previously described consensus clustering framework[74], [75]. 
 
Step 4: Filter coefficients in W matrix adaptively 
Inspection of the W matrix shows that in each metagene, the coefficients of most 
genes are very small around 0, and only a small number of genes have a coefficient 
significantly larger than 0. As each metagene is a positive linear combination of all the 
genes, a small coefficient indicates negligible contribution to the metagene. Thus the next 
step of our algorithm involves filtering out genes with small coefficients in each 
metagene. To do this, we first assume that the background distribution of coefficients 
fulfills an exponential distribution. We set a filtering threshold at the 95th percentile of the 
fitted exponential distribution and set all coefficients below this to zero. 
 
Step 5: Assign genes to the leading edge metagenes 
As each gene can contribute to more than one metagene we next need to assign 
each gene to a single metagene. We assigned genes to metagenes using the following 
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rules: (1) if one gene has no contribution to any of the metagenes, it is defined as not in 
any metagene; (2) otherwise each gene is assigned to the metagene in which it has the 
largest coefficient.  
4.3.2 Data preprocessing 
We analyzed 5 existing datasets of gene expression profiles of PBMC from 
vaccinated subjects at three time points, day 0, day 3 and day 7 respectively. The 5 
datasets covered 5 different vaccines with the following GEO accession IDs: GSE52245 
for MPSV4 and MCV4; GSE13485 for YF-17D; GSE29617 for TIV and GSE29615 for 
LAIV. The GenePattern module “CollapseDataset” was used to extract the expression 
values of genes from the raw data file and to map Affymetrix probes to gene 
symbols[76]. Then we applied quantile normalization and a log2 transformation to the 
expression data.  
4.3.3 Gene set enrichment analysis 
GSEA was employed as follows. Candidate genes are ranked by their differential 
expression between two phenotypes, day 0 vs. day 3 and day 0 vs. day 7 in our case. The 
statistic is a weighted Kolmogorov-Smirnov-like statistic and significance is calculated 
using an empirical permutation test[6]. We used the desktop version of GSEA software to 
conduct the leading edge analysis and extract the leading edge sparse matrix. While 
GSEA software recommends an FDR < 0.25 as the cutoff to select significantly enriched 
gene sets for leading edge analysis, we noticed that a universal cutoff across all the 
GSEA analyses gave wide variation in the number of enriched gene sets, ranging from 0 
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to around 600 gene sets. The number of gene sets satisfying this criterion was less than 5 
for six of the GSEA analyses, 186 for another, and between 186 and 550 for the 
remaining three. Thus, to make the metagene detection consistent, we used 500 as the 
number of top scoring gene sets for leading edge analysis for all the GSEA results. 
4.3.4 Calculate frequency of genes in the leading edges 
After generating a leading edge sparse matrix, we counted the frequency of each 
gene in the leading edges. To do this, we first converted the leading edge sparse matrix 
into a binary matrix, and summed the values in each column. We plotted a histogram to 
show the overall distribution.  
4.3.5 Circos plots  
To visualize the overlap in gene membership between groups of metagenes, we 
generated circos plots based on the number of genes in each metagene and the number of 
genes shared pairwise across metagenes. Circos plots were generated using the circos 
web tool (http://mkweb.bcgsc.ca/tableviewer/).  
4.3.6 Calculate the significance of overlaps between metagenes  
We used Fisher’s exact test to assess the significance of the number of genes 
shared by two metagenes. For example, to test the significance of association between 
Metagene 1 of LAIV at Day 3(M1.D3) versus Metagene 1 of LAIV at Day 7(M1.D7) we 
constructed a contingency table as follows. Under the null hypothesis, the probability of 
obtaining a shown set of values follows a hypergeometric distribution:  
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𝑝 = !!!! !!!!!!!!  
Where n = a + b + c + d 
 
 Genes in M1.D3 Genes not in M1.D3 
Genes in M1.D7 a b 
Genes not in M1.D7 c d 
 
 
4.3.7 Calculate the distance between two gene signatures based on metagenes 
Each phenotypic comparison (e.g. gene expression profiles of PBMC at day 0 
versus day 3 post-vaccination) generates a set of metagenes that represent a unique 
signature associated with that comparison. To calculate the distance between two gene 
signatures, we first compute the P values of Fisher’s exact test for each pairwise 
comparison of metagenes. The distance is then calculated as the sum of all the P values 
normalized to the total number of pairs[75]. We used this metric as an input for 
hierarchical clustering. 
 
4.4 Discussion 
Identifying coordinate up- or down-regulation of biologically meaningful sets of 
genes has become an important aspect of gene expression data analysis. Several large 
collections of biologically informative gene sets enable comprehensive annotation of 
experimental datasets using gene set enrichment analysis (GSEA). However the results of 
GSEA often include large numbers of gene sets that are enriched in the experimental 
dataset and the biological interpretation of each of the many enriched gene sets can prove 
challenging. Our LEM method allows for rapid identification of a small number of 
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metagenes common to multiple gene sets and coordinately unregulated in the 
experimental dataset of interest. This approach identifies metagenes that “explain” the 
enrichment of multiple gene sets. LEM analysis begins with a large group of enriched 
gene sets and reduces them to a smaller number of metagenes that correspond to specific 
biological themes present in the phenotype of interest. We applied this approach to 
identify the biological processes that are elicited by five different vaccines, and identified 
both shared and vaccine-specific components of the immune response to vaccination at 
different time points. 
Many gene sets in MSigDB are curated from expression profiles derived from 
experimental comparisons. As such, they often represent complex biological events, such 
as signatures induced by genetic perturbation or based on comparison of distinct 
differentiation states. It is therefore likely that many of these gene sets include multiple 
sub-signatures, each representing distinct biological processes. For instance, during the 
differentiation of effector CD8+ T cells from their naive precursors, there is a marked 
upregulation of sets of genes related to proliferation and also other genes related to 
effector T cell function. The GSE9650_NAIVE_VS_EFF_CD8_TCELL_DN gene set in 
MSigDB, therefore, contains genes related to mitosis (e.g. CDK1 and CDC34) as well as 
effector genes (e.g. GZMB and IFNG). The former class of genes is likely to be shared 
with activated and proliferating B cells, but not the latter. For some analytic purposes it 
might, therefore, be useful to test enrichment with gene sets that contain multiple 
biological processes that are initiated by complex stimuli such as receptor-ligand 
engagement, or cell differentiation. However this redundancy in gene sets returned in a 
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GSEA result can sometimes be challenging to interpret. The approach that we have 
developed extracts non-redundant LEM sub-signatures from the experimentally derived 
gene expression signatures. This approach achieves two goals: first, it reduces the 
complexity of the results of GSEA by reducing the number of gene sets that need to be 
evaluated; and second, it creates the refined set of metagenes in which key biological 
themes present in a phenotypic comparison of interest can be readily identified.  
The approach to clustering genes present in the leading edge of multiple gene sets 
is challenging because relatively few genes are present in multiple gene sets (Figure 
4.2B), resulting a sparse matrix of leading genes by gene sets. Analysis of sparse matrices 
are used required to solve diverse problems, such as social-network analysis [77] and 
regulatory networks in genes[78]. Low rank decompositions, such as SVD[79] and 
NMF[73] are powerful techniques for detecting latent low dimensional space and 
associated patterns from high dimensional data. However, a shortcoming of those 
methods stems from the fact that each principal component (in SVD) or parts (in NMF) is 
a linear combination of all the original variables, thus the resulting components/parts may 
be difficult to interpret biologically. Some methods have been applied to impose 
additional sparsity on the coefficients, such as sparse PCA[80] and sparse NMF[81], but 
they may in the dataset with extreme sparseness as ours (data not shown). Rather than 
explicitly add a sparse parameter into the objective function to impose sparsity constrains 
at the step of matrix factorization, we adaptively filtered coefficients after post-
factorization based on the distribution of coefficients. This approach is more 
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computationally efficient, can be easily adjusted to the sparseness of the low dimensional 
matrix, and makes the sparseness constraint more transparent to the user. 
Several reference collections of coordinately expressed modules of genes are 
currently available for the analysis of gene expression data. For instance, an analysis of 
246 subsets of mouse immune cells identified modules of genes with coordinated 
expression across diverse lineages, and to infer regulatory mechanisms controlling 
particular modules of genes[72]. In the human immune system, several studies have 
applied similar approaches to identify groups of co-regulated gene modules from 
expression profiles derived from PBMC samples representing a range of health and 
disease states[25], [82]. These PBMC modules have proven to be powerful tools for 
analyzing the human PBMC transcriptional response to infection, autoimmunity, and 
vaccination. However the statistical interdependence of the genes in a particular module 
is defined a priori, and therefore the module collection is static. The approach assumes 
that interdependence of gene expression in the previously defined modules will be 
maintained in all future experiments, an assumption that has not been exhaustively tested. 
In contrast, our approach re-defines the association of genes based on their co-regulation 
in each experimental dataset. Context-specific differences in the co-regulation of genes 
will therefore be captured by our approach, allowing for the construction of a set of 
metagenes‚ tailored to the specific experimental setting of interest. Additional studies will 
help define the extent of variation in the structure of leading edge metagenes from one 
biological context to another. 
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We have applied our approach to defining leading edge metagenes to the problem 
of identifying features of the transcriptional response to vaccination. We show that 
different vaccines elicit distinct kinetics of gene expression changes at day 3 and day 7 
post-vaccination compared to the pre-vaccination state. Vaccines such as YFV show 
marked similarity in gene expression at both timepoints, while MCV elicits a pattern of 
metagenes at day 3 that is quite distinct from that seen at day 7. This difference in the 
progression of biological changes elicited by vaccines underscores the difference in the 
biologic basis by which protein-conjugate and live viral vaccines elicit protective 
immune response. Consistent with this, the profile of metagenes elicited at day 3 by the 
five vaccines studied shows clear differences between vaccines comprising of protein-
conjugates (MPSV and MCV4) and those derived from viruses. However, by day 7 the 
pattern of metagenes elicited by the different viruses started to converge. This suggests 
that while different mechanisms may be responsible for the initial events in the priming 
of an immune response, common patterns of immune response begin to emerge at later 
timepoints. These findings have implications for the point at which gene-expression-
based predictors of vaccine response should be measured. 
We have also applied this approach to analyze the transcriptional response to 
sepsis in human samples and mouse models. The results suggest that there is highly 
significant conservation of gene expression between the species when measured at the 
gene set level. However, in addition to the conserved transcriptional programs, we also 
identified species-specific differences in the biological processes associated with sepsis. 
These findings help resolve contradictory observations regarding the extent of 
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evolutionary conservation in the transcriptional response to sepsis. (manuscript in 
preparation) Those projects suggest that LEM may be a general tool to detect and 
compare gene signatures by reducing the dimensionality of GSEA results. 
 
4.5 Contributions 
I conceived and developed the leading edge metagene (LEM) method and 
conducted all the computational analysis on 5 different vaccines.
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